Tenax Acquires Rights to Oral Levosimendan, Plans Phase 3 Trial in Type 2 PH

Tenax Acquires Rights to Oral Levosimendan, Plans Phase 3 Trial in Type 2 PH
5
(4)

Tenax Therapeutics  has acquired developmental and commercial rights for North America to an oral formulation of levosimendan, a potential therapy for pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF).

Tenax plans to open a Phase 3 safety and efficacy trial of oral levosimendan in patients with PH-HFpEF, a form of PH related to left heart disease (type 2) for which there are no approved therapies.

“Adding the oral formulation to our existing agreement represents a significant opportunity for us. Use of the currently available 1 mg capsule of levosimendan should allow us to conduct our upcoming Phase 3 trial with significantly faster enrollment versus the IV [intravenous] formulation,” Anthony DiTonno, CEO of Tenax, said in a press release.

Initially developed to treat heart failure, levosimendan is a calcium sensitizer that promotes heart contraction without increasing oxygen demand. The therapy also has a protective effect on the heart muscle, promotes blood vessel widening, and improves blood flow and oxygenation. In its intravenous form, it is available as Simdax in nearly 60 countries, but not the U.S., to treat acute heart failure.

Under a licensing agreement signed with Orion Corporation in 2013, Tenax acquired developmental and commercial rights of intravenous levosimendan for the U.S. and Canada. The expanded license agreement, called an amendment, extends those rights to the medication as an oral formulation.

The amendment also gives the company access to all the manufacturing, preclinical, and clinical data currently available for  oral levosimendan, a capsule formulation. That oral form has already been tested in a large number of patients, many for up to one year, the company reported.

One such trial was the REFALS (NCT03505021) study, in which 492 people with amyotrophic lateral sclerosis (ALS) were given levosimendan as 1 mg capsules once or twice daily for 48 weeks. Treatment was seen to be safe, but the trial failed to meet its primary goal of better respiratory and overall function in these patients.

Tenax recently completed a Phase 2 trial, called HELP (NCT03541603), assessing the safety and efficacy of intravenous levosimendan in patients with PH-HFpEF.

Data from this study showed that, compared with a placebo, levosimendan significantly reduced pulmonary capillary wedge pressure (PCWP) — a measure of blood pressure on the left side of heart — at rest, and improved patients’ physical capacity, as seen in increased distances covered in the six-minute walk test.

Treatment with intravenous levosimendan was also found to be safe and well tolerated.

“We expect an oral formulation will also enable us to enjoy greater market acceptance upon FDA approval for marketing,” DiTonno said.

Tenax intends to review its plans for oral levosimendan’s use in a future Phase 3 trial during its End-of-Phase 2 meeting with the U.S. Food and Drug Administration.

Joana holds a BSc in Biology, a MSc in Evolutionary and Developmental Biology and a PhD in Biomedical Sciences from Universidade de Lisboa, Portugal. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells — cells that made up the lining of blood vessels — found in the umbilical cord of newborns.
Total Posts: 329
Patrícia holds her PhD in Medical Microbiology and Infectious Diseases from the Leiden University Medical Center in Leiden, The Netherlands. She has studied Applied Biology at Universidade do Minho and was a postdoctoral research fellow at Instituto de Medicina Molecular in Lisbon, Portugal. Her work has been focused on molecular genetic traits of infectious agents such as viruses and parasites.
×
Joana holds a BSc in Biology, a MSc in Evolutionary and Developmental Biology and a PhD in Biomedical Sciences from Universidade de Lisboa, Portugal. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells — cells that made up the lining of blood vessels — found in the umbilical cord of newborns.
Latest Posts
  • self-help for anxiety
  • FDA, LIQ861
  • Liquidia, RareGen
  • levosimendan development agreement

How useful was this post?

Click on a star to rate it!

Average rating 5 / 5. Vote count: 4

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?